Evaluation of a multivariate prostate-specific antigen and percentage of free prostate-specific antigen logistic regression model in the diagnosis of prostate cancer

Tumor Biology

Volumn 20, Issue 6, 1999, Pages 312-318

  Filella, Xavier ^a,b   Alcover, Juan ^a   Quintó, Llorenç ^b   Molina, Rafael ^a   Bosch Capblanch, Xavier ^b   Carretero, Pablo ^a   Ballesta, Antonio Manuel ^a  

^a Department of Clinical Biochemistry ^*  (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Percentage of free prostate specific antigen; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; COMPLEX FORMATION; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REFERENCE VALUE; REGRESSION ANALYSIS; RISK BENEFIT ANALYSIS;

EID: 0032719302     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030095     Document Type: Article

References (16)

1. Ambruster DA: Prostate-specific antigen: Biochemistry, analytical methods, and clinical application. Clin Chem 1993;39:181-195.
2. Oesterling JE: Age-specific ranges for serum PSA. N Engl J Med 1996; 335:345-346.
3. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, Cooner WH: Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147:815-816.
4. Christensson A, Laurell CB, Lilja H: Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990;194: 755-763.
5. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222-226.
6. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T: Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 1991;37: 1618-1625.
7. van Iersel MP, Witjes WPJ, Thomas CMG, Segers MFG, Oosterhof GON, Debruyne FMJ: Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. Prostate 1996;7(suppl):48-57.
8. Abrahamsson PA, Lilja H, Oesterling JE: Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. Urol Clin North Am 1997;24:353-365.
9. Filella X, Alcover J, Molina R, Rodríguez A, Carretero P, Ballesta AM: Free and total PSA in the diagnosis of prostate cancer. Tumor Biol 1997;18:332-340.
10. Hanley JA, McNeil BJ: The meaning and use of the area under receiving operating characteristic (ROC) curve. Radiology 1982;143:29-36.
11. Leinonen J, Lövgren T, Vornanen T, Stenman UH: Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with α1-antichymotrypsin. Clin Chem 1993;39:2098-2103.
12. Luderer AA, Chen YT, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, Thiel RT: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic grey zone of total prostate-specific antigen. Urology 1995;46: 187-194.
13. Reissigl A, Klocker H, Pointner J, Ennemoser O, Falk M, Bartsch G: Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels. Prostate 1997;30:243-247.
14. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, de Kernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 1998; 279:1542-1547.
15. Stenman UH: Prostate-specific antigen, clinical use and staging: An overview. Br J Urol 1997;79 (suppl 1):53-60.
16. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC: Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5-12.